

Health NCP Net

Overview of the Health Calls 2026
and 2027 from Horizon Europe

www.healthncp.net



HNN3.0 (The Cluster 1 Health consortium of NCPs for Horizon Europe) has received funding from the European Union's Horizon EUROPE research and innovation programme under Grant Agreement number 101057279

DISCLAIMER: This document is provided for information only. The contents of this document are not legally binding. Please always check the official European Commission call documentation, including the call text and deadlines.

[Health-NCP-Net \(HNN3.0\)](#) is a European project of the Horizon Europe programme funded by the European Commission. The network facilitates trans-national cooperation between [National Contact Points \(NCPs\) for Cluster 1 “Health”](#) within Pillar II (Global Challenges and European Industrial Competitiveness) of Horizon Europe. HNN3.0 aims to align and enhance the services that NCPs provide applicants of European funding for Health research across Europe and to optimise the support for applicants. Our [HNN 3.0 services](#) are tailor-made to the needs of NCPs and applicants and are free of charge.

INTRODUCTION AND BACKGROUND

On December 12th, 2025, the European Commission published the [Horizon Europe work program for the Health Cluster](#) including calls for proposals for 2026/2027. In addition to the work programs for the various program components, the [general introduction](#) and [general annexes](#) have also been published. These contain important information, including details on the applicable rules for participation.

This document will provide you with a structured and clear table of the Cluster 1 ‘Health’ calls for 2026 and 2027, including a list of relevant and helpful information, e.g. Funding specifics and Cross cutting priorities.

The three planned COFUND actions relating to European partnerships (HORIZON-HLTH-2026-02-DISEASE-12, HORIZON-HLTH-2026-03-DISEASE-13, HORIZON-HLTH-2026-04-CARE-04) are not included in the list below, as they are aimed at national funders and not at the general research community.

CONTENT

Abbreviations	3
General Information for the Horizon Europe Work Programme 2026-2027 - Health	4
Topics 2026 - Single stage	6
Topics 2027 - Single stage / 1	10
Topics 2027 - Single stage / 2	13
Topics 2027 - Two stage	14

Abbreviations

MS and AC	Member States and Associated Countries	HTA	Health Technology Assessment
CSA	Coordination and Support Action	IHI-JU	Innovative Health Initiative Joint Undertaking
EHDS	European Health Data Space	JRC	Joint Research Centre
EMA	European Medicines Agency	LMICs	Low- and Middle-Income Countries
EOSC	European Open Science Cloud	PCP / PPI	Pre-Commercial Procurement
EP Permed	European Partnership for Personalised Medicine	PPI	Public Procurement of Innovative Solutions
ERA	European Research Area	RIA / IA	Research and Innovation Action / Innovation Action
ERDERA	European Rare Disease Research Alliance	SME	Start-ups, micro, small and medium-sized enterprises
ERIC	European Research Infrastructure Consortia	SSH	Social Sciences and Humanities
ERIs	European research infrastructures	TC	Third countries
GACD	Global Alliance for Chronic Diseases	THCS	European Partnership on Transforming Health and Care Systems

General Information for the Horizon Europe Work Programme 2026-2027 - Health:

- **Blind Evaluation:** If indicated in the specific call/topic conditions, first-stage proposals of two-stage submissions will be evaluated blindly and applicants must not disclose their identity in the proposal abstract and Part B of their proposal.
- **China eligibility to participate:**
 - o Legal entities established in China are not eligible to participate in both RIAs and IAs under all destinations. Exceptions may be granted on a case-by-case basis for justified reasons.
 - o For additional information, especially on the eligibility for entities controlled by China or by a legal entity established in China, please see the [Annex B](#) of the [General Annexes of the Work Programme 2026-2027](#).
- **Clinical Studies** are understood here as they are defined by the EU Commission in the "[Information on Clinical Studies](#)" document. If any planned activity within the project falls under this definition of a clinical study, this additional template should be used. The use of this template is expected for single-stage or stage-2 proposals. Please be advised that the template is offered for all topics in the Cluster Health. This does not mean that it is mandatory for all proposals submitted under Cluster Health topics. See also our annotated version of the application template with further recommendations and suggestions: "[Information on Clinical Studies - Annotated Template](#)".
- **European Research Infrastructures** (ERIs) may be exploited. Find an overview of the relevant [Health Research Infrastructures on our website](#). Health Research Infrastructures are networks, facilities, services, and resources that support high-quality, collaborative, and sustainable health research across European countries.
- **FAIR data:** FAIR data are data which meet the principles of findability, accessibility, interoperability, and reusability. Data may include, amongst others, exploitation of information, digital research data generated in the action, data from European research infrastructures and programmes such as Copernicus, European Space Agency and the GEO initiative. For further details, see the [FAIR principles](#), the [FAIR cookbook](#) and the [guides for researchers on how to make your data FAIR](#).
- The **JRC may participate** as member of the consortium selected for funding as a beneficiary with zero funding, or as an associated partner. The JRC will not participate in the preparation and submission of the proposal.
- **Lumps sum funding** in Horizon Europe projects is a simplified form of EU funding where the grant amount is fixed in advance and does not depend on the actual costs incurred. The EU Commission provides a collection of the most important information, guiding documents and links (including to recordings of past events) on [Lump sum Funding on the Funding and Tenders portal](#).

- **Pre-Commercial Procurement (PCP)** in Horizon Europe serves to promote research and development services in a competitive manner for a specific product or service that is not yet commercially available. For more information see recording and slides of our [HNN3.0 | Workshop "From Theory to Practice: Navigating Pre-Commercial Procurement in Horizon Europe"](#).
- **Portfolio Approach:** To ensure a balanced project portfolio, in some topics grants will be awarded (within available budget) to proposals not only in order of ranking but at least also to those proposals that are the highest ranked within different focus areas mentioned in the topic text (e.g. different viruses targeted). Provided that the proposals attain all thresholds.
- **SMEs:** Participation of start-ups, micro, small and medium-sized enterprises (SMEs) is also encouraged.
- **SSH** is listed in the table for those topics where it is specifically mentioned in the topic text. A specific analysis of SSH-relevant Topics in Work Programme 2026-2027 was done by Net4Society, the transnational network for Cluster 2 "Culture, Creativity and Inclusive Society", National Contact Points in Horizon Europe and published in the document "[Opportunities for Researchers from the Social Sciences and Humanities \(SSH\) in Horizon Europe](#)".
- **USA eligibility for funding:** In recognition of the opening of the US National Institutes of Health's programmes to European researchers, legal entities established in the United States of America may exceptionally participate as a beneficiary or affiliated entity, and are eligible to receive Union funding except for *HORIZON-HLTH-2027-03-TOOL-08: Towards Artificial General Intelligence (AGI) for healthcare* (limited to legal entities established in MS and AC).

Topics 2026 - Single stage

Opening: 10 Feb 2026, Deadline: 16 Apr 2026

Topic	Type of Action	Budget per project / overall [million €]	Indic. No. of projects funded	Cross cutting priorities	Lumps sum funding (LSF)	EU bodies/ ecosystems to use	Funding specifics	Clinical studies (CS) expected or possible
Destination 1 - Staying healthy in a rapidly changing society								
HORIZON-HLTH-2026-01-STAYHLTH-02: Behavioural interventions as primary prevention for Non-Communicable Diseases (NCDs) among young people	RIA	9-10 M€ / 20.6 M€	2	SSH FAIR data	-		NCDs explicitly exclude cancer.	CS expected
HORIZON-HLTH-2026-01-STAYHLTH-03: Building public trust and outreach in the life Sciences	CSA	1.5-1.9 M€ / 1.9 M€	1		LSF	JRC	Coordinators of projects must be legal entities established in an EU Member State or Associated Country	
Destination 2 - Living and working in a health-promoting environment								
HORIZON-HLTH-2026-01-ENVHLTH-01: Towards a better understanding and anticipation of the impacts of climate change on health	RIA	7-8 M€ / 55 M€	7	SSH FAIR data	LSF	EHDS EOSC	Portfolio Approach - proposals that are the highest ranked within different broad focus areas. Joint networking activities with a dedicated work package with ~ 2% of the total requested budget. Cooperation with LMICs is strongly encouraged.	CS possible
HORIZON-HLTH-2026-01-ENVHLTH-04: Towards climate resilient, prepared and carbon neutral populations and healthcare systems	RIA	7-8 M€ / 45 M€	6	SSH	LSF	ERIs in the environment and health domain	Joint networking activities with a dedicated work package with ~ 2% of the total requested budget. International cooperation is encouraged.	CS possible

HORIZON-HLTH-2026-01-ENVHLTH-05: Support for a multilateral initiative on climate change and health research	CSA	3 M€ / 3 M€	1		LSF		Coordinators of projects must be legal entities established in an EU Member State or Associated Country.	
Destination 3 - Tackling diseases and reducing disease burden								
HORIZON-HLTH-2026-01-DISEASE-02: Innovative interventions to prevent the harmful effects of using digital technologies on the mental health of children and young adults	RIA	8 M€ / 44.2 M€	6	SSH FAIR data SMEs	-	ERIs relevant for brain- research	Liaise with relevant EU projects on mental Health and the future co-funded EP Brain Health.	CS expected
HORIZON-HLTH-2026-01-DISEASE-03: Advancing research on the prevention, diagnosis, and management of post-infection long-term conditions	RIA	6-8 M€ / 39.3 M€	5	SSH FAIR data SMEs	LSF	ERIs where relevant EHDS EOSC	Engage early on with the EMA to ensure adequacy of the actions from a regulatory point of view. Where relevant, a HTA should be conducted. Research linked to cancer is excluded.	CS expected
HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential	RIA	9-11 M€ / 44.2 M€	5	SMEs	-	JRC	Portfolio Approach - proposals that are the highest ranked within different viruses targeted. Participation of TC where addressed viruses are endemic or where outbreaks have occurred or are ongoing is encouraged.	CS expected
HORIZON-HLTH-2026-01-DISEASE-09: Multisectoral approach to tackle chronic noncommunicable diseases: implementation research maximizing collaboration and coordination with sectors and in settings beyond the healthcare system (GACD)	RIA	3-4 M€ / 9.8 M€	3	SSH	LSF		Budget for networking and joint activities (e.g. GACD Meetings).	CS expected

HORIZON-HLTH-2026-01-DISEASE-11: Understanding of sex and/or gender-specific mechanisms of cardiovascular diseases: determinants, risk factors and pathways	RIA	6-7 M€ / 39.3 M€	6	SSH FAIR data SMEs	LSF	ERIs in the health domain	Budget for networking and joint activities.	CS possible
HORIZON-HLTH-2026-01-DISEASE-15: Scaling up innovation in cardiovascular health	CSA	1.9 M€ / 1.9 M€	1	SSH	LSF	EHDS	Coordinators of projects must be legal entities established in an EU Member State or Associated Country.	
Destination 4 - Ensuring equal access to innovative, sustainable, and high-quality healthcare								
HORIZON-HLTH-2026-01-CARE-01: Public procurement of innovative solutions for improving citizens' access to healthcare through integrated or personalized approaches	PPI	3-8 M€ / 24.5 M€	4	SMEs	-	ERIs in the health domain EHDS	Beneficiaries may provide financial support to third parties (max 60,000 € grants) to ensure deployment and impact of the project outcomes.	
HORIZON-HLTH-2026-01-CARE-03: Identifying and addressing low-value care in health and care systems	RIA	10 M€ / 38 M€	4		-	EU level initiatives (e.g. THCS) or other		CS possible
Destination 5 - Developing and using new tools, technologies and digital solutions for a healthy society								
HORIZON-HLTH-2026-01-TOOL-03: Integrating New Approach Methodologies (NAMs) to advance biomedical research and regulatory testing	RIA	5-8 M€ / 49 M€	7	FAIR data SMEs	LSF	JRC relevant ERIs EHDS	Joint networking activities with a dedicated work package with ~ 2% of the total requested budget.	CS possible
HORIZON-HLTH-2026-01-TOOL-05: Pilot actions for follow-on funding: Leveraging EU-funded collaborative research in regenerative medicine	IA	6-8 M€ / 29.5 M€	4		LSF		Focus on prototyping, demonstrating and validating health innovations from TRL 5. Proposals must be based on a prior multi-beneficiary project (completed max 3 years ago) funded under Horizon 2020 or Horizon Europe. Projects funded under Marie-	CS expected

							Skłodowska-Curie Actions are not eligible. Projects funded under co-funded EU Partnerships or ERANETs are eligible. Entities established in an eligible country but which are directly or indirectly controlled by China or by a legal entity established in China are not eligible to participate in the action.	
HORIZON-HLTH-2026-01-TOOL-06: Support to European Research Area (ERA) action on accelerating New Approach Methodologies (NAMs) to advance biomedical research and testing of medicinal products and medical devices	CSA	2.9 M€ / 2.9 M€	1	SMEs	LSF	JRC	The selected proposal should be coordinated by any active participant to the ERA action. Coordinators of projects must be legal entities established in an EU Member State or Associated Country.	
HORIZON-HLTH-2026-01-TOOL-07: Establishing a European network of Centres of Excellence (CoEs) for Advanced Therapies Medicinal Products (ATMPs)	CSA	3.9 M€ / 3.9 M€	1		LSF	JRC Liaise with relevant partnerships, e.g. ERDERA, EP Permed, IHI-JU	Coordinators of projects must be legal entities established in an EU Member State or Associated Country.	
Destination 6 - Maintaining an innovative, sustainable, and competitive EU health industry								
HORIZON-HLTH-2026-01-IND-03: Regulatory science to support translational development of patient-centred health technologies	RIA	4-6 M€ / 19.6 M€	4		LSF	ERIs active in the health domain		CS possible

Topics 2027 - Single stage / 1

Changed Opening: 29 Oct 2026, Changed Deadline: 17 Feb 2027

Topic	Type of Action	Budget per project / overall [million €]	Indic. No. of projects funded	Cross cutting priorities	Lumps sum funding (LSF)	EU bodies/ ecosystems to use	Funding specifics	Clinical studies (CS) expected or possible
Destination 1 - Staying healthy in a rapidly changing society								
HORIZON-HLTH-2027-01-STAYHLTH-01: Addressing disabilities through the life course to support independent living and inclusion	RIA	6-8 M€ / 39.3 M€	5	SSH	LSF	ERIs in the area of health		CS possible
Destination 2 - Living and working in a health-promoting environment								
HORIZON-HLTH-2027-01-ENVHLTH-02: Integrating climate-related exposures into the human exposome and characterising its changes in response to climate change	RIA	10-11 M€ / 45 M€	4	SSH FAIR data	LSF	JRC ERIs in the environment, climate and health domain	Proposals should ensure that chemical monitoring and human biomonitoring data are shared in the Common Data Platform for Chemicals and the environmental sustainability database. Joint networking activities with a dedicated work package with ~ 2% of the total requested budget. International cooperation is encouraged with regions that are under-represented in human exposome research.	CS possible
HORIZON-HLTH-2027-01-ENVHLTHMISSCLIMA-03: Tools and technologies to support health adaptation to climate change	PCP	4-5 M€ / 20 M€	4		-	ERIs in the environment, climate and health domain	Subcontracted work must be performed in EU MS and AC - unless otherwise approved by the granting authority.	

							Procurers are required to promote the call for tenders widely (MS/AC). Beneficiaries may provide financial support to third parties (max 60,000 € grants) to ensure deployment and impact of the project outcomes.	
Destination 3 - Tackling diseases and reducing disease burden								
HORIZON-HLTH-2027-01-DISEASE-05: Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential	RIA	9-11 M€ / 44.2 M€	5	SMEs	-	Relevant ERIs	Portfolio Approach - proposals that are the highest ranked within different viruses/groups of viruses targeted. Synergise with projects funded by the co-funded EU Partnership for Pandemic Preparedness. Antibodies and antibody derived proteins are excluded.	CS possible
HORIZON-HLTH-2027-01-DISEASE-06: Development of monoclonal antibodies to prevent and treat infections from Flaviviruses	RIA	9-10 M€ / 37.3 M€	4	SMEs	-	Relevant ERIs	Portfolio Approach - proposals that are the highest ranked within different Flaviviruses targeted. Participation of TC where addressed viruses are endemic or where outbreaks have occurred or are ongoing is encouraged.	CS expected
HORIZON-HLTH-2027-01-DISEASE-07: Development of monoclonal antibodies to prevent and treat infections from Filo-, Nairo-, Phenui-, Picorna- and Toga viruses	RIA	9-10 M€ / 37.3 M€	4	SMEs	-	Relevant ERIs	Portfolio Approach - proposals that are the highest ranked within different viruses targeted provided that the proposals attain all thresholds.	CS expected

							Participation of TC where addressed viruses are endemic or where outbreaks have occurred or are ongoing is encouraged.	
HORIZON-HLTH-2027-01-DISEASE-08: Development of innovative antimicrobials against pathogens resistant to antimicrobials	RIA	8-10 M€ / 44.2 M€	5	SMEs	-		Portfolio Approach - proposals that are the highest ranked within different pathogens targeted, provided. Participation of TC where AMR bacteria and fungi in the proposal are endemic or where outbreaks have occurred or are ongoing is encouraged.	CS expected
HORIZON-HLTH-2027-01-DISEASE-10: Prevention and management of chronic noncommunicable diseases in children and young people (GACD)	RIA	3-4 M€ / 11.8 M€	3	SSH	LSF		Budget networking and joint activities (e.g. GACD Meetings).	CS expected
Destination 4 - Ensuring equal access to innovative, sustainable, and high-quality healthcare								
HORIZON-HLTH-2027-01-CARE-02: Personalised approaches to reduce risks from Adverse Drug Reactions due to administration of multiple medications	RIA	8-10 M€ / 38 M€	4	SMEs	-	EP PerMed THCS	Data sharing with the relevant stakeholders and the EMA.	CS expected
Destination 6 - Maintaining an innovative, sustainable, and competitive EU health industry								
HORIZON-HLTH-2027-01-IND-01: Development of cell-free protein synthesis platforms for discovery and/or production of biologicals	RIA	6-8 M€ / 24.5 M€	4	SMEs	-			

Topics 2027 - Single stage / 2

Opening: 03 Jun 2027, Changed Deadline: 16 Sep 2027

Topic	Type of Action	Budget per project / overall [million €]	Indic. No. of projects funded	Cross cutting priorities	Lumps sum funding (LSF)	EU bodies/ ecosystems to use	Funding specifics	Clinical studies (CS) expected or possible
Destination 5 - Developing and using new tools, technologies and digital solutions for a healthy society								
HORIZON-HLTH-2027-03-TOOL-02: Advancing bio-printing of living cells for regenerative medicine	RIA	7-10 M€ / 39.3 M€	4	SMEs	-	JRC		CS expected
HORIZON-HLTH-2027-03-TOOL-04: Virtual Human Twins (VHTs) for integrated clinical decision support in prevention and diagnosis	RIA	10-12 M€ / 39.3 M€	4	SSH SMEs	-	Align with relevant EU initiatives, e.g. EU Cancer Imaging, 1+Million Genomes, Intensive Care Unit Data Space, EP Permed		CS expected
HORIZON-HLTH-2027-03-TOOL-08: Towards the next generation of frontier Artificial Intelligence models for healthcare	CSA	2.9 M€ / 2.9 M€	1	SSH	LSF	EHDS	Participation is limited to legal entities established in MS and AC. Proposals including entities established in countries outside the scope specified in the topic will be ineligible.	

Topics 2027 - Two stage

Changed Opening: 29 Oct 2026, Changed Deadlines: 17 Feb 2027 (1st stage), 16 Sep 2027 (2nd stage)

Topic	Type of Action	Budget per project / overall [million €]	Indic. No. of projects funded	Cross cutting priorities	Lumps sum funding (LSF)	EU bodies/ ecosystems to use	Funding specifics	Clinical studies (CS) expected or possible
Destination 3 - Tackling diseases and reducing disease burden								
HORIZON-HLTH-2027-02-DISEASE-01-two-stage: Innovative healthcare interventions for non-communicable diseases	RIA	7-8 M€ / 63.8 M€	8	SSH FAIR data SMEs	LSF	EHDS	Blind Evaluation Budget for networking and joint activities.	CS expected
HORIZON-HLTH-2027-02-DISEASE-14-two-stage: Clinical trials for advancing innovative interventions for neurodegenerative diseases	RIA	10 M€ / 39.3 M€	4	SSH FAIR data SMEs	-	Relevant ERIs	Blind Evaluation Rare neurodegenerative diseases are excluded. Budget for networking and joint activities. Rare neurodegenerative diseases are excluded.	CS expected
Destination 5 - Developing and using new tools, technologies and digital solutions for a healthy society								
HORIZON-HLTH-2027-02-TOOL-01-two-stage: Development of predictive biomarkers of disease progression and treatment response by using AI methodologies for chronic noncommunicable diseases	RIA	6-8 M€ / 44.2 M€	6	SMEs	-	Relevant ERIs and/or data Infrastructures (Digital Europe Programme) in the area of health	Blind Evaluation Budget for networking and joint activities.	CS expected
Destination 6 - Maintaining an innovative, sustainable, and competitive EU health industry								
HORIZON-HLTH-2027-02-IND-02-two-stage:	IA	5-7 M€ / 39.3 M€	6		LSF		Blind Evaluation	CS expected

Portable and versatile Point-of-care diagnostics							Entities established in an eligible country but which are directly or indirectly controlled by China or by a legal entity established in China are not eligible to participate in the action.	
--	--	--	--	--	--	--	---	--